Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 30+ AI models, with 0% extra fees
DeepMind CEO laments that AI commercialization is too rapid: if more time had been spent in laboratories for a few more years, humanity might have already conquered cancer
Google DeepMind CEO Demis Hassabis laments that the rush in AI commercial competition is too hasty; if the technology had been refined in laboratories for a few more years, humanity might have already conquered cancer.
AI is rapidly transforming humanity, with new technologies and tools emerging every few weeks or even days, but Demis Hassabis, CEO of Google DeepMind and 2024 Nobel laureate in Chemistry, believes that the pace of AI competition is too hurried. If he had his way, AI would spend more years in labs honing its capabilities, and perhaps humans would have already solved cancer.
Hassabis shared this sentiment about current AI development during a podcast with video journalist Cleo Abram. In a past interview with Time magazine, he described himself as a scientist, emphasizing that his exploration of AI is driven by a pursuit of knowledge and understanding of the world.
He mentioned that his initial motivation for entering the AI field was not to create chatbots, but to accelerate scientific discovery. Their most famous achievement is AlphaFold, a system that solved the “protein folding problem,” which had eluded biologists for 50 years. Hassabis pointed out that this benefits over three million scientists worldwide, especially in research on diseases like malaria, as AI provides free structural databases, allowing researchers to skip basic experiments and move directly into drug development.
Image source: YouTube AlphaFold research results, which contributed to Hassabis becoming a Nobel laureate.
He believes that if AI had been allowed to stay longer in labs focusing on such critical issues, humanity might have already made more decisive breakthroughs in cancer treatment or materials science.
Cutting-edge technology reaching the public in just months, yet key problems lose resources
In the interview, Hassabis outlined his ideal path for AI development—what he calls the “CERN model.” He hopes that the process of developing artificial general intelligence (AGI) can be as rigorous, cautious, and thoughtful as the European Organization for Nuclear Research (CERN) operating the Large Hadron Collider, ensuring progress only after thorough understanding of each step.
However, reality has diverged from Hassabis’s ideal script. The explosion of ChatGPT and breakthroughs in generative AI at the end of 2022 sparked a chaotic global business race. He admits that this situation has accelerated AI deployment, with advanced technologies reaching the public in just months, but it has also diverted resources away from truly critical issues.
To gain market and technological leadership, development has been forced into high-speed progress. Hassabis confesses that they can no longer develop technology at the slow, philosophically reflective pace he once envisioned, carefully evaluating each next step.
While AI chatbots are useful for summarization and brainstorming, they inherently still suffer from issues like hallucinations. Yet, commercial pressures have pushed these experimental products rapidly into the mainstream market. This has resulted in a large portion of R&D focus and resources being channeled into the cycle of releasing general foundational models aimed at mass use.
To balance reality and ideals, Hassabis adopts a more pragmatic approach—leading Google’s consumer AI products like Gemini, while also investing in applied AI (Narrow AI). He believes there’s no need to wait for AGI; systems like AlphaFold that solve specific problems can already bring tangible benefits in energy, materials science, and healthcare.
AlphaGo’s legendary move reveals AI’s potential to surpass human thinking
Hassabis’s confidence in AI largely stems from the 2016 AlphaGo match against South Korean Go master Lee Sedol. During that game, AlphaGo played the famous “Move 37,” which was initially mocked as an unlikely move, but ultimately led to AlphaGo’s victory.
Image source: gogameguru.com The move played by AlphaGo that defied human Go strategies was seen by Hassabis as a sign that AI could break through human cognitive frameworks.
From this signal, Hassabis realized that AI had developed the ability to go beyond human experience and seek entirely new solutions. He aims to apply this creative capacity—surpassing human thinking—to science.
AlphaFold exemplifies this mindset. Traditional methods require hundreds of thousands of dollars and years to determine a single protein structure, but AlphaFold 2 has predicted nearly 200 million known protein structures.
Now, Hassabis is leading his team into deeper drug discovery. Traditional drug development takes about ten years with only a 10% success rate. He founded Isomorphic Labs, which uses AlphaFold 3 and subsequent models for “virtual screening.” AI can simulate millions of compound-protein interactions in minutes, while also checking for toxicity across over 20k human proteins, allowing most failures to be filtered out in silico before laboratory testing, thus only the most promising candidates proceed to experimental validation.
Concerns about two risks AI might bring
However, as AI technology advances into an era of AI agents, Hassabis’s concerns about the future have become more concrete. He categorizes the risks into two main types: the first is “malicious actors”—individuals or nations who might misuse technologies originally intended for curing diseases or developing new materials for harmful purposes.
The second, more sci-fi but real threat, is “going rogue.” When systems become extremely intelligent and autonomous, ensuring they execute human-set goals precisely and do not bypass safety measures becomes an extremely difficult technical challenge.
In response to these challenges, Hassabis calls for leading AI research institutions, governments, and academia to establish international cooperation mechanisms, emphasizing that the final mile toward AGI requires more safety research.
Despite regrets that AI couldn’t stay longer in labs, Hassabis remains optimistic about the next 50 years. He envisions AI helping humanity unlock nuclear fusion, discover room-temperature superconductors, and even reduce space travel energy costs to zero. To him, AI is not just a technology but a magnifying glass for exploring the universe’s truths. Whatever the answers may be, he is eager to find out.